Admin
Categories
- alectinib – Alecensa from Chugai – Roche – GenenTech
- Anaplastic Large-Cell Lymphomas
- ASP3026 from Astellas
- Brain metastases
- brigatinib-Alunbrig from Takeda
- CEP-37440
- ceritinib – Zykadia from Novartis
- crizotinib – Xalkori from Pfizer
- Experiences
- Glioblastomas
- Imunotherapies
- JH-VIII-157-02
- lorlatinib – Lorbrena by Pfizer
- Lung cancer
- Neuroblastomas
- NMS-E628
- PLB1003 – Beijing Pearl Biotechnology
- Potential Treatments
- Regulatory applications & approvals
- Research
- Resistance to treatment
- RXDX-101 – entrectinib – by Ignyta
- Side Effects
- TPX-0005: TP Therapeutics
- TSR-011 from Tesaro
- Uncategorized
- X-396 – ensartinib from Xcovrery
Category Archives: lorlatinib – Lorbrena by Pfizer
Patients can live a median of 6.8 years after stage 4 diagnosis
A study of 110 patients at the University of Colorado found that 50% of patients live 6.8 years or longer. These were patients who had access to multiple ALK inhibitors through clinical trials at that research University. That University also … Continue reading
Impact of EML4-ALK Variants on resistance
As of April 20, 2018 Study of 2 groups of patients. Group A = 129 patients, Group B = 577 patients. The most frequent variants were Variant 1 (43%) and Variant 3 (40%). “ALK resistance mutations were significantly more common … Continue reading
Article on latest develpments
In January 2016 an article was published that reviewed the current status of nine 2nd generation and 3rd generation ALK inhibitors, some HSP 90 inhibitors and briefly 2 immunotherapies for lung cancer. Much of that research has been described in … Continue reading
Posted in alectinib - Alecensa from Chugai - Roche - GenenTech, ASP3026 from Astellas, brigatinib-Alunbrig from Takeda, CEP-37440, ceritinib - Zykadia from Novartis, Imunotherapies, lorlatinib - Lorbrena by Pfizer, Lung cancer, NMS-E628, Potential Treatments, Research, Resistance to treatment, RXDX-101 - entrectinib - by Ignyta, Side Effects, TSR-011 from Tesaro, X-396 - ensartinib from Xcovrery
Leave a comment